- Total income
- ₹4,797 Cr
- Profit
- ₹1,885 Cr
About Natco Pharma
Natco Pharma is a publicly listed company based in Hyderabad (India) founded in 1981 by Venkaiah Chowdary Nannapaneni. APIs and finished dosage forms are developed and manufactured. The company has 5,060 employees. Natco Pharma has completed 1 acquisition, including Dash Pharmaceuticals. Its chief executive, as recorded, is Rajeev Nannapaneni. Its website natcopharma.co.in draws about 20 thousand monthly visits. Its Indian entity Natco Pharma Limited reported revenue of βΉ4,376 Cr. Natco Pharma offers products and services including Generic Drugs and Active Pharmaceutical Ingredients. Its focus areas include Traditional Pharmaceuticals, Generics and Diversified.
Company details
Natco Pharma was founded in 1981 and is headquartered in Hyderabad, India. Operations are focused on the pharmaceutical sector, where active pharmaceutical ingredients and finished dosage forms are developed and manufactured. A pipeline of generic drugs is maintained, alongside a drug discovery research program in oncology. Emphasis is placed on niche therapeutic areas, complex products, contract manufacturing, and marketing of drug formulation services.
Natco Pharma is ranked #485 on the Fortune India 500 (2025).
Recognitions & Rankings of Natco Pharma
- Valuation
- ₹26,610 Cr
- Headquarters Hyderabad, India
- Employees 5,060
- Founders Venkaiah Chowdary Nannapaneni
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website natcopharma.co.in
- Social LinkedIn X Facebook
- Legal Name Natco Pharma Limited
- Market Cap₹16,098 Cr
NATCOPHARM · NSE
- Share Price₹821.95
+0.16% today
- Revenue₹4,078 Cr
FY 2025-26 · -7.9% YoY
- EBITDA₹1,436 Cr
Margin 35.2%
- Net Profit₹1,437 Cr
FY 2025-26 · -23.7% YoY
- P/E (TTM)19.6x
P/B 1.5x
- ROE16.3%
ROCE 17.0%
- Debt / Equity0.06
Interest cover 3.0x
- Latest Funding Round$143.25M (USD), Post-IPO
Dec 2017
- InvestorsMultiples Alternate Asset Management
& 2 more
- Employee Count5,060
- Investments & Acquisitions
Associated legal entities of Natco Pharma
Natco Pharma operates through Natco Pharma Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Natco Pharma Limited Listed CIN L24230TG1981PLC003201 | Active | 19 Sep 1981 | Hyderabad, Telangana | ₹4,376 Cr | 4,652 | 11 | View details |
Products & Services of Natco Pharma
Natco Pharma offers a comprehensive portfolio of products and services, including Generic Drugs and Active Pharmaceutical Ingredients.
Generic versions of oncology drugs are developed and marketed to enhance affordability in domestic and international markets
Active pharmaceutical ingredients are manufactured and supplied from specialized facilities to support formulation needs
Funding Insights of Natco Pharma
- Total Rounds 5
- Last Round Post-IPO β $143.25M
- First Round $5.5M
(Dec 2011)
- Investors Count 3
All 5 funding rounds of Natco Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2017 | $143.25M | Post-IPO | β | β | β |
| Oct 2017 | Post-IPO | β | β | ||
| Dec 2013 | $18M | Post-IPO | β | β | |
| Dec 2011 | $3.55M | Post-IPO | β | β | β |
| Dec 2011 | $5.5M | Post-IPO | β | β |
3 investors in total: 3 institutional.
Investors in Natco Pharma
Natco Pharma has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Multiples Alternate Asset Management, CX Partners and Kotak Investment Advisors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment partnerships, entrepreneur support, and profit-focused services in finance. | 2009 | multiplesequity.com | Mumbai, India | |
Private equity investments in India are managed by CX Partners. | cxpartners.in | Delhi, India | ||
Provider of investment advisory services | Mumbai, India |
Investor details for Natco Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Natco Pharma Limited (Natco Pharma)
Natco Pharma Limited is the primary company behind Natco Pharma. The board of Natco Pharma Limited currently have 9 directors; the longest-serving is Rajeev Nannapaneni, appointed in 2012. 20 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Rajeev Nannapaneni DIN 00183872 | Whole-time director | 01 Jun 2012 | 14 yrs 5 mo | Natco Pharma Limited |
| Potluri Prasad Sivaramakrishna DIN 07011140 | Whole-time director | 12 Nov 2014 | 12 yrs | Natco Pharma Limited |
| Lingarao Donthineni DIN 07088404 | Whole-time director | 11 Feb 2015 | 11 yrs 9 mo | Natco Pharma Limited |
| Venkaiah Chowdary Nannapaneni DIN 00183315 | Managing Director | 01 Apr 2015 | 11 yrs 7 mo | Natco Pharma Limited |
| Agnihotra Dakshina Murty Chavali DIN 00374673 | Director | 01 Apr 2024 | 2 yrs 7 mo | Natco Pharma Limited |
| Vijayabhaskar Dronadula DIN 07158951 | Director | 01 Apr 2024 | 2 yrs 7 mo | Natco Pharma Limited |
| Nitin Jain DIN 00136245 | Director | 12 Aug 2024 | 2 yrs 3 mo | Natco Pharma Limited |
| Suma Kantipudi DIN 02734369 | Director | 12 Aug 2024 | 2 yrs 3 mo | Natco Pharma Limited |
| Lakshminarayana Bolisetty DIN 02766709 | Director | 12 Aug 2024 | 2 yrs 3 mo | Natco Pharma Limited |
People of Natco Pharma
55 people are tracked at Natco Pharma (22 in leadership, 5 in board & advisors, 28 in team); the tracked headcount is 5,060.
| Name | Role | Group |
|---|---|---|
| Founder & Managing Director | Leadership | |
| CEO | Leadership | |
Sadasiva Rao N | VP, Corporate Affairs, Legal & Secretarial, Estate Management | Leadership |
Venkat Rao Tummala | VP, Manufacturing, Chemical Division | Leadership |
Subba Rao Mente | VP, Global Generics | Leadership |
Sunil Kotaru | VP, Supply Chain Management | Leadership |
Appa Rao S V V N | CFO | Leadership |
Ravi Kiran Namburi | VP, Marketing & Sales, Domestic | Leadership |
Srinivas Ch | VP, Demand & Supply Planning | Leadership |
Vamsi Krishna Mutyala | Associate Vice President- CSR | Leadership |
Sandeep Kumar | Senior Vice President | Leadership |
Rajneesh Kumar Sharma | Deputy General Manager | Leadership |
Dr. Sashikanth Suthrapu | Deputy General Manager | Leadership |
Amresh T. | Head Of Legal | Leadership |
Sara Narsaiah | Sales & Marketing Head, CHS Division - India 1(south & Central) | Leadership |
Tanmoy Mondal | Deputy General Manager | Leadership |
Wahid Khan | General Manager, NDDS | Leadership |
Ramesh Rudraraju | DGM (multi Unit) - HR Head | Leadership |
Ravinder Reddy Banala | AGM Financial Planning And Analysis | Head Commercial | Leadership |
Shailesh. Indulkar | Zonal Business Head | Leadership |
35 more people are available in the full profile.
Complete people profiles for Natco Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Natco Pharma
Natco Pharma is a publicly listed company on the NSE with ticker symbol NATCOPHARM in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date27 Dec 1995
- Listed onNSE: NATCOPHARM
- Listed entityNATCO Pharma Limited
- Exchange sectorHealth technology
- ISININE987B01026
- Share price₹788.15 (-0.13% on the day) · 2026-10-14
- Market capitalisation₹15,489 Cr
- Price to earnings12.4
- EPS (diluted, trailing year)₹63.37
- Dividend yield0.56%
- Volume (last session)242,146
Financials of Natco Pharma
Exchange-reported figures of Natco Pharma Limited, the listed company behind Natco Pharma (NSE: NATCOPHARM).
Financial Highlights
FY 2025-26 Β· ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 4,078 | 4,430 | 3,999 | 2,707 | 1,945 | 2,052 | 1,915 |
| Revenue growth | -7.9% | +10.8% | +47.7% | +39.2% | -5.2% | +7.2% | - |
| EBITDA | 1,436 | 2,196 | 1,751 | 936 | 264 | 606 | 583 |
| EBITDA margin | +35.2% | +49.6% | +43.8% | +34.6% | +13.6% | +29.5% | +30.4% |
| Profit before tax | 1,491 | 2,291 | 1,674 | 862 | 202 | 580 | 569 |
| Net profit | 1,437 | 1,884 | 1,390 | 701 | 137 | 417 | 448 |
| Net profit margin | +35.2% | +42.5% | +34.8% | +25.9% | +7.1% | +20.3% | +23.4% |
| EPS (βΉ) | 79.25 | 105.33 | 77.56 | 39.19 | 9.32 | 24.16 | 25.32 |
| Balance sheet | |||||||
| Total assets | 10,002 | 7,962 | 6,299 | 5,128 | 4,776 | 4,492 | 4,192 |
| Net worth | 9,221 | 7,607 | 5,853 | 4,874 | 4,264 | 4,122 | 3,774 |
| Total debt | 714 | 279 | 371 | 167 | 416 | 268 | 316 |
| Cash & bank | 1,551 | 2,176 | 953 | 546 | 206 | 284 | 66.00 |
| Net working capital | 3,403 | 4,280 | 2,973 | 2,178 | 1,980 | 1,934 | 1,927 |
| Cash flow | |||||||
| Cash from operations | 1,768 | 1,697 | 1,212 | 849 | 46.50 | 299 | 417 |
| Cash from investing | (1,987) | (1,436) | (1,026) | (465) | 4.00 | (107) | (175) |
| Cash from financing | 298 | (211) | (247) | (363) | 34.80 | (186) | (251) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 967 | 735 | 739 | 647 | 1,363 | 1,329 | 1,221 | 475 |
| Revenue growth (YoY) | -29.0% | -44.7% | -39.5% | +36.3% | -0.6% | -2.5% | - | - |
| Other income | 52.10 | 59.20 | 77.80 | 58.10 | 100 | 61.70 | 66.30 | 176 |
| EBITDA | 258 | 186 | 128 | 159 | 579 | 571 | 548 | 38.80 |
| EBITDA margin | +26.7% | +25.4% | +17.3% | +24.5% | +42.5% | +43.0% | +44.9% | +8.2% |
| Depreciation | 49.20 | 47.10 | 50.40 | 46.20 | 52.40 | 57.60 | 98.30 | 47.00 |
| Interest | 17.60 | 13.00 | 10.90 | 9.50 | 13.10 | 3.20 | 10.20 | 4.40 |
| Profit before tax | 243 | 186 | 144 | 161 | 614 | 572 | 506 | 164 |
| Tax | 69.80 | 63.40 | (89.20) | 20.70 | 95.80 | 91.60 | 99.90 | 31.30 |
| Net profit | 173 | 122 | 233 | 140 | 518 | 480 | 406 | 132 |
| EPS (βΉ) | 11.31 | 11.53 | 14.96 | 8.46 | 28.94 | 26.84 | 22.70 | 7.43 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 3,595 | 4,094 | 3,569 | 2,351 | 1,768 | 1,654 | 1,790 |
| Revenue growth | -12.2% | +14.7% | +51.8% | +33.0% | +6.9% | -7.6% | - |
| EBITDA | 1,305 | 2,144 | 1,637 | 845 | 213 | 418 | 578 |
| EBITDA margin | +36.3% | +52.4% | +45.9% | +35.9% | +12.1% | +25.3% | +32.3% |
| Profit before tax | 1,364 | 2,226 | 1,555 | 771 | 156 | 392 | 583 |
| Net profit | 1,282 | 1,778 | 1,309 | 622 | 105 | 285 | 462 |
| Net profit margin | +35.7% | +43.4% | +36.7% | +26.5% | +6.0% | +17.2% | +25.8% |
| EPS (βΉ) | 71.55 | 103.37 | 72.99 | 34.91 | 7.62 | 16.96 | 26.07 |
| Balance sheet | |||||||
| Total assets | 9,329 | 7,679 | 6,033 | 4,950 | 4,688 | 4,448 | 4,274 |
| Net worth | 8,553 | 7,334 | 5,592 | 4,702 | 4,192 | 4,091 | 3,870 |
| Total debt | 709 | 275 | 366 | 161 | 400 | 256 | 314 |
| Cash & bank | 1,187 | 1,857 | 865 | 412 | 101 | 263 | 54.10 |
| Net working capital | 2,788 | 3,807 | 2,726 | 1,946 | 1,788 | 1,863 | 1,888 |
| Cash flow | |||||||
| Cash from operations | 1,776 | 1,662 | 1,196 | 784 | 57.70 | 184 | 422 |
| Cash from investing | (2,078) | (1,444) | (960) | (437) | (92.50) | (3.20) | (165) |
| Cash from financing | 302 | (212) | (237) | (347) | 35.60 | (183) | (261) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 854 | 597 | 609 | 529 | 1,264 | 1,193 | 1,157 | 408 |
| Revenue growth (YoY) | -32.4% | -50.0% | -47.4% | +29.7% | -2.2% | -3.6% | - | - |
| Other income | 40.30 | 48.30 | 72.90 | 55.30 | 93.30 | 59.60 | 62.10 | 168 |
| Total expenses | 638 | 491 | 516 | 408 | 712 | 653 | 596 | 378 |
| EBITDA | 216 | 106 | 92.40 | 120 | 552 | 540 | 561 | 29.40 |
| EBITDA margin | +25.3% | +17.8% | +15.2% | +22.7% | +43.7% | +45.3% | +48.5% | +7.2% |
| Depreciation | 44.00 | 42.70 | 45.60 | 42.10 | 48.10 | 53.80 | 93.70 | 43.70 |
| Interest | 15.60 | 9.60 | 9.70 | 8.30 | 11.70 | 2.60 | 8.80 | 3.40 |
| Profit before tax | 197 | 102 | 110 | 125 | 586 | 543 | 521 | 150 |
| Tax | 53.80 | 27.40 | (99.60) | 18.30 | 85.10 | 78.80 | 92.70 | 25.40 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 967 | 735 | 739 | 647 | 1,363 | 1,329 | 1,221 | 475 |
| Revenue growth (YoY) | -29.0% | -44.7% | -39.5% | +36.3% | -0.6% | -2.5% | - | - |
| Other income | 52.10 | 59.20 | 77.80 | 58.10 | 100 | 61.70 | 66.30 | 176 |
| EBITDA | 258 | 186 | 128 | 159 | 579 | 571 | 548 | 38.80 |
| EBITDA margin | +26.7% | +25.4% | +17.3% | +24.5% | +42.5% | +43.0% | +44.9% | +8.2% |
| Depreciation | 49.20 | 47.10 | 50.40 | 46.20 | 52.40 | 57.60 | 98.30 | 47.00 |
| Interest | 17.60 | 13.00 | 10.90 | 9.50 | 13.10 | 3.20 | 10.20 | 4.40 |
| Profit before tax | 243 | 186 | 144 | 161 | 614 | 572 | 506 | 164 |
| Tax | 69.80 | 63.40 | (89.20) | 20.70 | 95.80 | 91.60 | 99.90 | 31.30 |
| Net profit | 173 | 122 | 233 | 140 | 518 | 480 | 406 | 132 |
| EPS (βΉ) | 11.31 | 11.53 | 14.96 | 8.46 | 28.94 | 26.84 | 22.70 | 7.43 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 4,078 | 4,430 | 3,999 | 2,707 | 1,945 | 2,052 | 1,915 |
| Revenue growth | -7.9% | +10.8% | +47.7% | +39.2% | -5.2% | +7.2% | - |
| Other income | 298 | 354 | 128 | 105 | 99.00 | 104 | 107 |
| Total expenses | 2,642 | 2,234 | 2,247 | 1,772 | 1,681 | 1,446 | 1,332 |
| Employee cost | 687 | 594 | 525 | 487 | 445 | 415 | 375 |
| EBITDA | 1,436 | 2,196 | 1,751 | 936 | 264 | 606 | 583 |
| EBITDA margin | +35.2% | +49.6% | +43.8% | +34.6% | +13.6% | +29.5% | +30.4% |
| Depreciation | 207 | 235 | 187 | 164 | 143 | 117 | 99.80 |
| Interest | 36.70 | 23.90 | 19.20 | 14.50 | 17.70 | 13.30 | 21.50 |
| Profit before tax | 1,491 | 2,291 | 1,674 | 862 | 202 | 580 | 569 |
| Tax | 119 | 408 | 285 | 147 | 32.20 | 137 | 111 |
| Net profit | 1,437 | 1,884 | 1,390 | 701 | 137 | 417 | 448 |
| Net profit margin | +35.2% | +42.5% | +34.8% | +25.9% | +7.1% | +20.3% | +23.4% |
| EPS (βΉ) | 79.25 | 105.33 | 77.56 | 39.19 | 9.32 | 24.16 | 25.32 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 35.80 | 35.80 | 35.80 | 36.50 | 36.50 | 36.50 | 36.40 |
| Reserves & surplus | 9,185 | 7,571 | 5,817 | 4,837 | 4,227 | 4,085 | 3,737 |
| Shareholders' funds (net worth) | 9,221 | 7,607 | 5,853 | 4,874 | 4,264 | 4,122 | 3,774 |
| Minority interest | 0.00 | 5.30 | 0.00 | 0.00 | 0.00 | 1.80 | 11.20 |
| Secured loans | 573 | 182 | 167 | 74.90 | 289 | 128 | 134 |
| Unsecured loans | 141 | 97.60 | 204 | 91.80 | 126 | 139 | 182 |
| Total debt | 714 | 279 | 371 | 167 | 416 | 268 | 316 |
| Total liabilities | 10,002 | 7,962 | 6,299 | 5,128 | 4,776 | 4,492 | 4,192 |
| Assets | |||||||
| Gross block | 4,256 | 4,016 | 3,603 | 3,375 | 3,127 | 2,702 | 2,149 |
| Net block | 2,803 | 2,698 | 2,491 | 2,427 | 2,312 | 2,023 | 1,584 |
| Capital work in progress | 294 | 225 | 137 | 64.30 | 130 | 223 | 518 |
| Investments | 3,127 | 474 | 539 | 392 | 308 | 304 | 112 |
| Inventories | 908 | 766 | 700 | 743 | 762 | 798 | 558 |
| Sundry debtors | 881 | 1,247 | 1,189 | 856 | 621 | 413 | 551 |
| Cash & bank balances | 1,551 | 2,176 | 953 | 546 | 206 | 284 | 66.00 |
| Loans & advances | 1,134 | 761 | 738 | 550 | 694 | 698 | 1,122 |
| Total current assets | 4,474 | 4,949 | 3,580 | 2,695 | 2,283 | 2,193 | 2,297 |
| Total current liabilities | 1,071 | 669 | 607 | 518 | 303 | 259 | 370 |
| Net working capital | 3,403 | 4,280 | 2,973 | 2,178 | 1,980 | 1,934 | 1,927 |
| Total assets | 10,002 | 7,962 | 6,299 | 5,128 | 4,776 | 4,492 | 4,192 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 120 | 70.40 | 132 | 111 | 25.80 | 19.80 | 28.30 |
| Net cash from operating activities | 1,768 | 1,697 | 1,212 | 849 | 46.50 | 299 | 417 |
| Net cash from investing activities | (1,987) | (1,436) | (1,026) | (465) | 4.00 | (107) | (175) |
| Net cash from financing activities | 298 | (211) | (247) | (363) | 34.80 | (186) | (251) |
| Net change in cash | 78.90 | 49.60 | (61.50) | 20.80 | 85.30 | 6.00 | (8.50) |
| Closing cash | 1,551 | 2,176 | 953 | 546 | 206 | 284 | 66.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -7.9% | +10.8% | +47.7% | +39.2% | -5.2% | +7.2% | - |
| EBITDA growth | -34.6% | +25.4% | +87.2% | +255.1% | -56.5% | +4.1% | - |
| PBT growth | -34.9% | +36.9% | +94.2% | +326.3% | -65.1% | +1.9% | -31.0% |
| Net income growth | -23.7% | +35.5% | +98.4% | +410.1% | -67.1% | -7.0% | - |
| Revenue CAGR (3Y) | +14.6% | +31.6% | +24.9% | +12.2% | -2.4% | -2.1% | -1.8% |
| EBITDA CAGR (3Y) | +15.4% | +102.8% | +42.4% | +17.1% | -30.8% | -13.3% | -5.2% |
| Profitability & leverage | |||||||
| Net income margin | +33.6% | +42.5% | +34.7% | +26.4% | +8.7% | +21.6% | +23.9% |
| Return on capital employed | +17.0% | +32.5% | +29.6% | +17.7% | +3.8% | +13.7% | +14.5% |
| Return on net worth | +16.3% | +28.0% | +25.9% | +15.7% | +3.3% | +11.2% | +12.6% |
| Debt / equity | 0.06 | 0.05 | 0.05 | 0.06 | 0.08 | 0.07 | 0.10 |
| Long-term debt / equity | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 2.98 | 1.22 | 1.23 | 1.88 | 14.64 | 2.72 | 4.45 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.99 | 1.16 | 1.15 | 0.83 | 0.67 | 0.85 | 1.00 |
| Inventory turnover | 4.87 | 6.04 | 5.54 | 3.60 | 2.49 | 3.03 | 3.52 |
| Debtors turnover | 3.83 | 3.64 | 3.91 | 3.67 | 3.76 | 4.26 | 3.62 |
| EPS (βΉ) | 79.25 | 105.33 | 77.56 | 39.19 | 9.32 | 24.16 | 25.32 |
| Dividend per share (βΉ) | 5.00 | 6.00 | 9.50 | 5.50 | 4.50 | 5.25 | 6.75 |
| Book value per share (βΉ) | 515.15 | 424.97 | 326.99 | 267.06 | 233.62 | 225.84 | 207.34 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 854 | 597 | 609 | 529 | 1,264 | 1,193 | 1,157 | 408 |
| Revenue growth (YoY) | -32.4% | -50.0% | -47.4% | +29.7% | -2.2% | -3.6% | - | - |
| Other income | 40.30 | 48.30 | 72.90 | 55.30 | 93.30 | 59.60 | 62.10 | 168 |
| Total expenses | 638 | 491 | 516 | 408 | 712 | 653 | 596 | 378 |
| EBITDA | 216 | 106 | 92.40 | 120 | 552 | 540 | 561 | 29.40 |
| EBITDA margin | +25.3% | +17.8% | +15.2% | +22.7% | +43.7% | +45.3% | +48.5% | +7.2% |
| Depreciation | 44.00 | 42.70 | 45.60 | 42.10 | 48.10 | 53.80 | 93.70 | 43.70 |
| Interest | 15.60 | 9.60 | 9.70 | 8.30 | 11.70 | 2.60 | 8.80 | 3.40 |
| Profit before tax | 197 | 102 | 110 | 125 | 586 | 543 | 521 | 150 |
| Tax | 53.80 | 27.40 | (99.60) | 18.30 | 85.10 | 78.80 | 92.70 | 25.40 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 3,595 | 4,094 | 3,569 | 2,351 | 1,768 | 1,654 | 1,790 |
| Revenue growth | -12.2% | +14.7% | +51.8% | +33.0% | +6.9% | -7.6% | - |
| Other income | 281 | 321 | 105 | 85.50 | 94.60 | 101 | 124 |
| Total expenses | 2,290 | 1,950 | 1,932 | 1,506 | 1,555 | 1,236 | 1,212 |
| Employee cost | 0.00 | 515 | 455 | 426 | 410 | 380 | 356 |
| EBITDA | 1,305 | 2,144 | 1,637 | 845 | 213 | 418 | 578 |
| EBITDA margin | +36.3% | +52.4% | +45.9% | +35.9% | +12.1% | +25.3% | +32.3% |
| Depreciation | 190 | 220 | 172 | 151 | 138 | 115 | 98.10 |
| Interest | 32.30 | 19.60 | 14.50 | 8.60 | 13.30 | 11.30 | 20.60 |
| Profit before tax | 1,364 | 2,226 | 1,555 | 771 | 156 | 392 | 583 |
| Tax | 82.60 | 376 | 249 | 134 | 16.80 | 82.70 | 109 |
| Net profit | 1,282 | 1,778 | 1,309 | 622 | 105 | 285 | 462 |
| Net profit margin | +35.7% | +43.4% | +36.7% | +26.5% | +6.0% | +17.2% | +25.8% |
| EPS (βΉ) | 71.55 | 103.37 | 72.99 | 34.91 | 7.62 | 16.96 | 26.07 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 35.80 | 35.80 | 35.80 | 36.50 | 36.50 | 36.50 | 36.40 |
| Reserves & surplus | 8,517 | 7,298 | 5,556 | 4,666 | 4,155 | 4,055 | 3,833 |
| Shareholders' funds (net worth) | 8,553 | 7,334 | 5,592 | 4,702 | 4,192 | 4,091 | 3,870 |
| Secured loans | 706 | 273 | 167 | 74.90 | 289 | 128 | 134 |
| Unsecured loans | 2.90 | 1.50 | 199 | 86.20 | 110 | 128 | 180 |
| Total debt | 709 | 275 | 366 | 161 | 400 | 256 | 314 |
| Total liabilities | 9,329 | 7,679 | 6,033 | 4,950 | 4,688 | 4,448 | 4,274 |
| Assets | |||||||
| Gross block | 3,994 | 3,784 | 3,360 | 3,157 | 2,978 | 2,678 | 2,134 |
| Net block | 2,615 | 2,517 | 2,287 | 2,234 | 2,174 | 2,006 | 1,574 |
| Capital work in progress | 293 | 225 | 134 | 62.80 | 129 | 223 | 518 |
| Investments | 3,265 | 855 | 742 | 658 | 550 | 337 | 191 |
| Inventories | 724 | 642 | 597 | 616 | 698 | 769 | 524 |
| Sundry debtors | 760 | 1,178 | 1,077 | 793 | 576 | 400 | 537 |
| Cash & bank balances | 1,187 | 1,857 | 865 | 412 | 101 | 263 | 54.10 |
| Loans & advances | 1,076 | 721 | 708 | 534 | 674 | 695 | 1,120 |
| Total current assets | 3,746 | 4,398 | 3,246 | 2,355 | 2,048 | 2,126 | 2,235 |
| Total current liabilities | 958 | 591 | 521 | 409 | 260 | 263 | 347 |
| Net working capital | 2,788 | 3,807 | 2,726 | 1,946 | 1,788 | 1,863 | 1,888 |
| Total assets | 9,329 | 7,679 | 6,033 | 4,950 | 4,688 | 4,448 | 4,274 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 11.20 | 5.50 | 6.90 | 5.90 | 5.10 | 7.90 | 11.50 |
| Net cash from operating activities | 1,776 | 1,662 | 1,196 | 784 | 57.70 | 184 | 422 |
| Net cash from investing activities | (2,078) | (1,444) | (960) | (437) | (92.50) | (3.20) | (165) |
| Net cash from financing activities | 302 | (212) | (237) | (347) | 35.60 | (183) | (261) |
| Net change in cash | 0.30 | 5.70 | (1.40) | 1.00 | 0.80 | (2.80) | (3.60) |
| Closing cash | 1,187 | 1,857 | 865 | 412 | 101 | 263 | 54.10 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -12.2% | +14.7% | +51.8% | +33.0% | +6.9% | -7.6% | - |
| EBITDA growth | -39.2% | +31.0% | +93.8% | +296.6% | -49.0% | -27.8% | - |
| PBT growth | -38.7% | +43.1% | +101.8% | +394.4% | -60.3% | -32.7% | -31.2% |
| Net income growth | -27.9% | +35.9% | +110.3% | +491.1% | -63.1% | -38.3% | - |
| Revenue CAGR (3Y) | +15.2% | +32.3% | +29.2% | +9.5% | -3.8% | -7.5% | -2.9% |
| EBITDA CAGR (3Y) | +15.6% | +115.9% | +57.7% | +13.5% | -36.1% | -23.4% | -5.8% |
| Profitability & leverage | |||||||
| Net income margin | +35.7% | +45.2% | +36.6% | +27.1% | +7.9% | +18.7% | +26.5% |
| Return on capital employed | +16.4% | +32.8% | +28.6% | +16.2% | +2.8% | +9.3% | +14.6% |
| Return on net worth | +16.1% | +28.6% | +25.4% | +14.3% | +2.5% | +7.8% | +12.8% |
| Debt / equity | 0.06 | 0.05 | 0.05 | 0.06 | 0.08 | 0.07 | 0.09 |
| Long-term debt / equity | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 2.90 | 1.02 | 0.99 | 1.24 | 17.83 | 3.74 | 4.29 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.92 | 1.15 | 1.10 | 0.77 | 0.63 | 0.69 | 0.94 |
| Inventory turnover | 5.26 | 6.61 | 5.88 | 3.58 | 2.41 | 2.56 | 3.47 |
| Debtors turnover | 3.71 | 3.63 | 3.82 | 3.44 | 3.62 | 3.53 | 3.48 |
| EPS (βΉ) | 71.59 | 103.37 | 72.99 | 34.91 | 7.62 | 16.96 | 26.07 |
| Dividend per share (βΉ) | 5.00 | 6.00 | 9.50 | 5.50 | 4.50 | 5.25 | 6.75 |
| Book value per share (βΉ) | 477.80 | 409.72 | 312.42 | 257.64 | 229.69 | 224.17 | 212.61 |
Investments & Acquisitions by Natco Pharma
Natco Pharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Dash Pharmaceuticals.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Advanced spectroscopic and laser instrumentation is developed for industrial applications. | dashpharm.com | Upper Saddle River, United States | 2014 | Dec 2021 | $18M |
Complete acquisition details for Natco Pharma
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Natco Pharma
5 dated milestones of Natco Pharma across 40 years, from founding to its latest funding, stage changes and deals.
- Founded Natco Pharma is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $5.5M.
- Funding Latest funding round, Post-IPO, of $143.2M.
- Acquisition Acquires Dash Pharmaceuticals.
Web traffic of Natco Pharma
The website of Natco Pharma (natcopharma.co.in) receives about 19.8K visits a month and ranks #1,133,324 among all websites worldwide, #1,401 in Biotechnology and Pharmaceuticals.
- Monthly visits19.8K
▼ 3.4% vs previous month
- Unique visitors7.1K
per month
- Global rank#1,133,324
among all websites
- Category rank#1,401
Health · Biotechnology and Pharmaceuticals
- Bounce rate36%
- Pages per visit3.3
- Average visit3 min 16 sec
- DevicesDesktop 37% Β· Mobile 63%
Websites whose visitors overlap most with Natco Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| glandpharma.com | 100% | 8.4K | #3,685,423 | View details | |
| smspharma.com | 91% | 3K | #2,783,668 | View details | |
| aurobindo.com | 88% | 24.4K | #1,029,164 | View details | |
| ajantapharma.com | 86% | 20.1K | #1,412,069 | View details | |
| shanthabiotech.com | 85% | View details | |||
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 34 similar websites and full traffic analytics for Natco Pharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 34 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Traditional Health & Nutrition
3 companies that operate in the same segment as Natco Pharma (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Oral solid drug delivery systems are manufactured and developed. | 1985 | Mumbai, Maharashtra, India | USD 42.49 M | USD 72.52 M | 1,115 | |
Generic, semi-solid, and liquid dosage forms are manufactured. | 1990 | Bengaluru, Karnataka, India | USD 508.93 M | 4,050 | ||
Specialty generic pharmaceuticals and APIs are manufactured and marketed. | 1983 | Mumbai, Maharashtra, India | USD 6.44 B | 19,801 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Natco Pharma
Complete news archive for Natco Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Natco Pharma
Natco Pharma was founded in 1981 and raised its 1st funding round 30 years after it was founded.
Natco Pharma is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
Rajeev Nannapaneni is the CEO of Natco Pharma, as recorded in our data.
Natco Pharma has 5,060 employees.
The primary company behind Natco Pharma, Natco Pharma Limited, reported revenue of βΉ4,376 Cr for FY 2026, down 8% year on year.
Natco Pharma was founded in 1981 and is headquartered in Hyderabad, India. Operations are focused on the pharmaceutical sector, where active pharmaceutical ingredients and finished dosage forms are developed and manufactured. A pipeline of generic drugs is maintained, alongside a drug discovery research program in oncology. Emphasis is placed on niche therapeutic areas, complex products, contract manufacturing, and marketing of drug formulation services.
Natco Pharma offers Generic Drugs and Active Pharmaceutical Ingredients.
Yes, Natco Pharma is publicly traded on NSE under the ticker symbol NATCOPHARM.
Natco Pharma has made 1 acquisition, including Dash Pharmaceuticals.
Natco Pharma has 3 investors. Key investors include Multiples Alternate Asset Management, CX Partners, and Kotak Investment Advisors.
Natco Pharma operates through Natco Pharma Limited.
The legal entities of Natco Pharma currently have 11 directors, including Potluri Prasad Sivaramakrishna, Lingarao Donthineni, Venkat Ramesh Chekuri and others.

